AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31939583 — intervention group
Group type: EXPERIMENTAL
Intervention: Home physical exercise program (10 weeks)
Number of subjects: 52
Study 30516259 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) administered intravenously to Group A
Number of subjects: 70
Study 30516259 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 70
Study 27654971 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD8931 20 mg + anastrozole
Number of subjects: 359
Study 27654971 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD8931 40 mg + anastrozole
Number of subjects: 359
Study 27654971 — intervention group
Group type: COMPARATOR
Intervention: Placebo + anastrozole
Number of subjects: 359
Study 27654971 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD8931 20 mg
Number of subjects: 359
Study 27654971 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD8931 40 mg
Number of subjects: 359
Study 27654971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 359
Study 25034315 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (2,000 IU/day)
Number of subjects: 58
Study 25034315 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 22728647 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided internet-delivered cognitive behaviour therapy (ICBT)
Number of subjects: 174
Study 20797774 — intervention group
Group type: EXPERIMENTAL
Intervention: Short thromboprophylaxis (stopping at Day 10±2)
Number of subjects: 857
Study 20797774 — intervention group
Group type: COMPARATOR
Intervention: Extended thromboprophylaxis (continuing up to Day 35±5)
Number of subjects: 857
Study 20797774 — intervention group
Group type: EXPERIMENTAL
Intervention: Short thromboprophylaxis (in patients with asymptomatic distal deep-vein thrombosis)
Number of subjects: 857
Study 20797774 — intervention group
Group type: COMPARATOR
Intervention: Extended thromboprophylaxis (in patients with asymptomatic distal deep-vein thrombosis)
Number of subjects: 857
Study 20797774 — intervention group
Group type: EXPERIMENTAL
Intervention: Short thromboprophylaxis
Number of subjects: 857
Study 20797774 — intervention group
Group type: COMPARATOR
Intervention: Extended thromboprophylaxis
Number of subjects: 857
Study 17727981 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral-appliance therapy
Number of subjects: 28
Study 17727981 — intervention group
Group type: COMPARATOR
Intervention: CPAP therapy
Number of subjects: 28
Study 16911345 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (1200 mg/day)
Number of subjects: 141
Study 16911345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 14622683 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Analog Scale (VAS) ratings of 0 to 4 mm
Number of subjects: 248
Study 14622683 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Analog Scale (VAS) ratings of 5 to 44 mm
Number of subjects: 248
Study 14622683 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Analog Scale (VAS) ratings of 45 to 74 mm
Number of subjects: 248
Study 14622683 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Analog Scale (VAS) ratings of 75 to 100 mm
Number of subjects: 248
Study 14622683 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage change in VAS score
Number of subjects: 248
Study 14622683 — intervention group
Group type: EXPERIMENTAL
Intervention: 33% decrease in pain
Number of subjects: 248
Study 11703619 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg
Number of subjects: 364
Study 11703619 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 364
Study 9129477 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplement (1000 mg supplemental Ca/d as calcium citrate malate)
Number of subjects: 26
Study 9129477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 8198899 — intervention group
Group type: COMPARATOR
Intervention: Control (carrier gas)
Number of subjects: 12
Study 8198899 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.04 MAC enflurane
Number of subjects: 12
Study 8198899 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.07 MAC enflurane
Number of subjects: 12
Study 8198899 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.13 MAC enflurane
Number of subjects: 12
Study 8198899 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.07 MAC enflurane (Design 2)
Number of subjects: 12
Study 3444801 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate day corticosteroid treatment
Number of subjects: 0
Study 30338694 — intervention group
Group type: EXPERIMENTAL
Intervention: Ear protectors
Number of subjects: 24
Study 30338694 — intervention group
Group type: COMPARATOR
Intervention: No ear protectors (control)
Number of subjects: 24
Study 30715100 — intervention group
Group type: COMPARATOR
Intervention: Blood pressure treatment goal
Number of subjects: 4268
Study 28969626 — intervention group
Group type: EXPERIMENTAL
Intervention: AyuFlex1 (250 mg twice daily)
Number of subjects: 105
Study 28969626 — intervention group
Group type: EXPERIMENTAL
Intervention: AyuFlex2 (500 mg twice daily)
Number of subjects: 105
Study 28969626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 25277305 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mg intravitreal ranibizumab injections
Number of subjects: 0
Study 25277305 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg intravitreal ranibizumab injections
Number of subjects: 0
Study 23513061 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-duration transient visual evoked potential (SD-tVEP)
Number of subjects: 75
Study 23513061 — intervention group
Group type: EXPERIMENTAL
Intervention: Low contrast (Lc) SD-tVEP
Number of subjects: 75
Study 23513061 — intervention group
Group type: EXPERIMENTAL
Intervention: High contrast (Hc) SD-tVEP
Number of subjects: 75
Study 23513061 — intervention group
Group type: EXPERIMENTAL
Intervention: SD-tVEP
Number of subjects: 75
Study 21744187 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 28
Study 21744187 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 28
Study 19143691 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg ondansetron
Number of subjects: 5161
Study 19143691 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5161
Study 16112244 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (20 mg once daily for 24 weeks)
Number of subjects: 192
Study 16112244 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (80 mg once daily for 24 weeks)
Number of subjects: 192
Study 16112244 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril plus Telmisartan (after 24 weeks of monotherapy for an additional 28 weeks)
Number of subjects: 192
Study 15312391 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal hyperthermic chemoperfusion (IHCP) combined with intravenous chemotherapy
Number of subjects: 82
Study 15312391 — intervention group
Group type: COMPARATOR
Intervention: Intravenous chemotherapy only
Number of subjects: 82
Study 11783600 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril (0.2 mg/kg/day)
Number of subjects: 0
Study 11783600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9129478 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate protein (MP; 23 g)
Number of subjects: 20
Study 9129478 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate protein plus potassium bicarbonate (MP+K; 23 g + 23 mmol KHCO3)
Number of subjects: 20
Study 9129478 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein (HP; 53 g)
Number of subjects: 20
Study 9129478 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein plus potassium bicarbonate (HP+K; 53 g + 70 mmol KHCO3)
Number of subjects: 20
Study 9129478 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein plus sodium chloride (HP+Na; 53 g + 70 mmol NaCl)
Number of subjects: 20
Study 9129478 — intervention group
Group type: COMPARATOR
Intervention: Moderate protein plus phosphate (MP+Pi; 23 g + 7.5 mmol phosphate)
Number of subjects: 20
Study 9129478 — intervention group
Group type: COMPARATOR
Intervention: Moderate protein (MP)
Number of subjects: 20
Study 8498389 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion program (low-cost, $30/year, individualized, delivered through mail)
Number of subjects: 4712
Study 8498389 — intervention group
Group type: COMPARATOR
Intervention: Risk appraisals only (first 12 months) then full intervention (second 12 months)
Number of subjects: 4712
Study 8498389 — intervention group
Group type: COMPARATOR
Intervention: Claims data only (control group)
Number of subjects: 4712
Study 31603106 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast Conservation Therapy (BCT)
Number of subjects: 170
Study 31603106 — intervention group
Group type: COMPARATOR
Intervention: Modified Radical Mastectomy (MRM)
Number of subjects: 170
Study 30392341 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV testing
Number of subjects: 63931
Study 30392341 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytology
Number of subjects: 63931
Study 30392341 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual inspection via acetic acid or Lugol's iodine (VIA/VILI)
Number of subjects: 63931
Study 30392341 — intervention group
Group type: COMPARATOR
Intervention: HPV positive group
Number of subjects: 63931
Study 30392341 — intervention group
Group type: COMPARATOR
Intervention: Cytology-positive group
Number of subjects: 63931
Study 27265844 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone gel (TRT, n = 20)
Number of subjects: 39
Study 27265844 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 19)
Number of subjects: 39
Study 24940942 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 SPMC sachets (split doses)
Number of subjects: 200
Study 24940942 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 SPMC sachets (split doses)
Number of subjects: 200
Study 24940942 — intervention group
Group type: COMPARATOR
Intervention: 4 L PEG in the morning on the day of colonoscopy
Number of subjects: 200
Study 24940942 — intervention group
Group type: COMPARATOR
Intervention: 2 L split doses of PEG
Number of subjects: 200
Study 24940942 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (SPMC and PEG)
Number of subjects: 200
Study 24940942 — intervention group
Group type: EXPERIMENTAL
Intervention: SPMC
Number of subjects: 200
Study 23041738 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 130/0.4
Number of subjects: 52
Study 23041738 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 130/0.42
Number of subjects: 52
Study 20175411 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable-pressure CPAP
Number of subjects: 200
Study 20175411 — intervention group
Group type: COMPARATOR
Intervention: Fixed-pressure CPAP
Number of subjects: 200
Study 18627321 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol ER 100 mg
Number of subjects: 2031
Study 18627321 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol ER 200 mg
Number of subjects: 2031
Study 18627321 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol ER 300 mg
Number of subjects: 2031
Study 18627321 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol ER 400 mg
Number of subjects: 2031
Study 18627321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2031
Study 16149140 — intervention group
Group type: EXPERIMENTAL
Intervention: American ginseng (AG) supplementation for 4 weeks
Number of subjects: 13
Study 16149140 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation for 4 weeks
Number of subjects: 13
Study 11933558 — intervention group
Group type: EXPERIMENTAL
Intervention: Omapatrilat
Number of subjects: 0
Study 11933558 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril
Number of subjects: 0
Study 11933558 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 0
Study 10418911 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPa (Infanrix, SmithKline Beecham, Biologicals)
Number of subjects: 226
Study 10418911 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced antigen formulation (dtpa, SmithKline Beecham Biologicals)
Number of subjects: 226
Study 10418911 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental low dose formulation (dtpa-exp; d and t, Michigan Biologic Products Institute)
Number of subjects: 226
Study 7560662 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin
Number of subjects: 11
Study 7560662 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline
Number of subjects: 11
Study 2405089 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release metoprolol 200 mg once daily
Number of subjects: 22
Study 2405089 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 100 mg once daily
Number of subjects: 22
Study 2405089 — intervention group
Group type: COMPARATOR
Intervention: Placebo run-in period
Number of subjects: 22
Study 7403993 — intervention group
Group type: EXPERIMENTAL
Intervention: econazole (Ecostatin; Squibb) for 7 days
Number of subjects: 330
Study 7403993 — intervention group
Group type: EXPERIMENTAL
Intervention: econazole (Ecostatin; Squibb) for 14 days
Number of subjects: 330
Study 30335191 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab and/or lapatinib during gestation (exposed group)
Number of subjects: 92
Study 30335191 — intervention group
Group type: COMPARATOR
Intervention: No trastuzumab and/or lapatinib during gestation (unexposed group)
Number of subjects: 92
Study 30335191 — intervention group
Group type: COMPARATOR
Intervention: Pregnant patients (n = 85)
Number of subjects: 92
Study 29128712 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized feedback intervention
Number of subjects: 109
Study 29128712 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control (AOC)
Number of subjects: 109
Study 27230875 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotational Atherectomy + Cutting Balloon (RA + CB)
Number of subjects: 71
Study 27230875 — intervention group
Group type: COMPARATOR
Intervention: Rotational Atherectomy (RA)
Number of subjects: 71
Study 24298947 — intervention group
Group type: COMPARATOR
Intervention: Non-ST elevation myocardial infarction (non-STEMI) patients
Number of subjects: 102
Study 24298947 — intervention group
Group type: COMPARATOR
Intervention: Stable angina (SA) patients
Number of subjects: 102
Study 24298947 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy controls
Number of subjects: 102
Study 24298947 — intervention group
Group type: COMPARATOR
Intervention: Patients with sustained NK cell deficit
Number of subjects: 102
Study 24298947 — intervention group
Group type: COMPARATOR
Intervention: Patients with pronounced increase in NK cells
Number of subjects: 102
Study 24298947 — intervention group
Group type: COMPARATOR
Intervention: Patients with failure to reconstitute NK cell levels
Number of subjects: 102
Study 24298947 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients during 12-month follow-up
Number of subjects: 102
Study 22294704 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-fraction schedule of whole-breast radiotherapy following local excision of early breast cancer
Number of subjects: 915
Study 19961336 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline bone turnover markers (S-TRACP5b)
Number of subjects: 1040
Study 19961336 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline bone turnover markers (S-CTX-I)
Number of subjects: 1040
Study 19961336 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary osteocalcin (measured at 1-year visit)
Number of subjects: 1040
Study 19961336 — intervention group
Group type: EXPERIMENTAL
Intervention: Resorption markers (average of two measurements)
Number of subjects: 1040
Study 19961336 — intervention group
Group type: EXPERIMENTAL
Intervention: S-TRACP5b, S-CTX-I, and urinary osteocalcin
Number of subjects: 1040
Study 17503039 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET/CT before and after neo-adjuvant CRT
Number of subjects: 48
Study 16376765 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 73
Study 16376765 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratio of early mitral inflow velocity to mitral annular velocity
Number of subjects: 73
Study 16376765 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline heart rate
Number of subjects: 73
Study 16376765 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma levels of B-type natriuretic peptide
Number of subjects: 73
Study 11926722 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (titrated from 40 mg to 120 mg/day)
Number of subjects: 173
Study 11926722 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine, 20 mg q.d.
Number of subjects: 173
Study 11926722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study 11926722 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 173
Study 9535211 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with peripheral blood progenitor cell transplantation (PBPCT) after two cycles of conventional chemotherapy (etoposide 500 mg/m2, ifosfamide 4 g/m2, cisplatin 50 mg/m2, epirubicin 50 mg/m2 plus granulocyte colony-stimulating factor 5 microg/kg) followed by high-dose etoposide 1,500 mg/m2, ifosfamide 12 g/m2, carboplatin 750 mg/m2, and epirubicin 150 mg/m2 with PBPCT.
Number of subjects: 16
Study 9535211 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection in stages I to IIIA patients before high-dose chemotherapy.
Number of subjects: 16
Study 9535211 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional chemotherapy followed by high-dose chemotherapy and PBPCT.
Number of subjects: 16
Study 7614524 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release 5-ISMN 60 mg once daily
Number of subjects: 24
Study 7614524 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release 5-ISMN 120 mg once daily
Number of subjects: 24
Study 7614524 — intervention group
Group type: COMPARATOR
Intervention: ISDN 40 mg every 6 hours
Number of subjects: 24
Study 7614524 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 24
Study 2577308 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (120 mg/day)
Number of subjects: 12
Study 2577308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 406602 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil, 80 mg three times/day
Number of subjects: 13
Study 406602 — intervention group
Group type: COMPARATOR
Intervention: Practolol, 100 mg three times/day
Number of subjects: 13
Study 406602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 30658629 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training: resistance + aerobic exercise program for nine months (n=18)
Number of subjects: 36
Study 30658629 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=18)
Number of subjects: 36
Study 28844992 — intervention group
Group type: EXPERIMENTAL
Intervention: CT coronary angiography (CTCA)
Number of subjects: 3770
Study 26854054 — intervention group
Group type: EXPERIMENTAL
Intervention: Zero end‐expiratory pressure (ZEEP), n=25
Number of subjects: 50
Study 26854054 — intervention group
Group type: COMPARATOR
Intervention: +5 PEEP, n=25
Number of subjects: 50
Study 24033910 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraventricular injection of low-dose rtPA
Number of subjects: 0
Study 24033910 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intraventricular injection of normal saline)
Number of subjects: 0
Study 22726860 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordinated inpatient rehabilitation system of care
Number of subjects: 26
Study 20074703 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (4.0 microg/kg IV)
Number of subjects: 23
Study 20074703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 17628683 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg ranibizumab
Number of subjects: 716
Study 17628683 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab
Number of subjects: 716
Study 17628683 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (both dosages combined)
Number of subjects: 716
Study 17628683 — intervention group
Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 716
Study 16125026 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-contact, 20-week clinical nursing intervention
Number of subjects: 237
Study 16125026 — intervention group
Group type: COMPARATOR
Intervention: Conventional care control group
Number of subjects: 237
Study 12543995 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise and physiotherapy program (PTEX), n = 27, 12-week program, 3 times per week, 60 to 90 minutes per session, resistance and aerobic exercises at 70 to 85% of maximal effort
Number of subjects: 53
Study 12543995 — intervention group
Group type: COMPARATOR
Intervention: Home-delivered physical and occupational therapy (PT), n = 26, no supervised exercise
Number of subjects: 53
Study 10549211 — intervention group
Group type: EXPERIMENTAL
Intervention: Oro-mandibular dysfunction, anxiety, muscular stress
Number of subjects: 102
Study 10549211 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 102
Study 9117191 — intervention group
Group type: EXPERIMENTAL
Intervention: Trainees
Number of subjects: 85
Study 9117191 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructors
Number of subjects: 85
Study 9117191 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 85
Study 1803995 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine 300 mg daily
Number of subjects: 41
Study 1803995 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine 600 mg daily
Number of subjects: 41
Study 1803995 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine 1500 mg daily
Number of subjects: 41
Study 1803995 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine 300 mg daily plus acyclovir 4800 mg daily
Number of subjects: 41
Study 1803995 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine 600 mg daily plus acyclovir 4800 mg daily
Number of subjects: 41
Study 1803995 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine 1500 mg daily plus acyclovir 4800 mg daily
Number of subjects: 41
Study 1803995 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of zidovudine
Number of subjects: 41